Fennec Pharmaceuticals annual gross margin
2022
2023
Fennec Pharmaceuticals's gross margin was 84.07% for fiscal 2023.
View full Fennec Pharmaceuticals company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | 84.07% | +2.16 pp |
| 2022 | 2022-12-31 | 81.91% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q4 2023 | 2023-12-31 | 73.79% | — |
| Q3 2023 | 2023-09-30 | 94.92% | — |
| Q2 2023 | 2023-06-30 | 95.55% | — |
| Q1 2023 | 2023-03-31 | 94.34% | — |
Across the available reported history, Fennec Pharmaceuticals's gross margin increased from 81.91% to 84.07%, a change of +2.16 percentage points. The latest reported quarter, Q4 2023, shows 73.79%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fennec Pharmaceuticals filings at SEC.gov ↗